Evidence map›Paper›PMID 31418763›Full record

ArticleBioinformatics (Oxford, England)2020

AntiHIV-Pred: web-resource for in silico prediction of anti-HIV/AIDS activity.

Leonid Stolbov, Dmitry Druzhilovskiy, Anastasia Rudik, Dmitry Filimonov, Vladimir Poroikov, Marc Nicklaus

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Leonid StolbovLaboratory for Structure-Function Based Drug Design, Institute of Biomedical Chemistry, Moscow 119121, Russia.
Dmitry DruzhilovskiyLaboratory for Structure-Function Based Drug Design, Institute of Biomedical Chemistry, Moscow 119121, Russia.
Anastasia RudikLaboratory for Structure-Function Based Drug Design, Institute of Biomedical Chemistry, Moscow 119121, Russia.
Dmitry FilimonovLaboratory for Structure-Function Based Drug Design, Institute of Biomedical Chemistry, Moscow 119121, Russia.
Vladimir PoroikovLaboratory for Structure-Function Based Drug Design, Institute of Biomedical Chemistry, Moscow 119121, Russia.
Marc NicklausCADD Group, Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Frederick, Frederick, MD 21702, USA.
Institute of Biomedical Chemistry · RUNational Institutes of Health · US

Funding

HIV Integrase Modeling and Computer-Aided Inhibitor DevelopmentZIABC010524 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NICKLAUS, MARC · 2009 to 2024
$2.6M
6 · The paper itself

Abstract

motivationIdentification of new molecules promising for treatment of HIV-infection and HIV-associated disorders remains an important task in order to provide safer and more effective therapies. Utilization of prior knowledge by application of computer-aided drug discovery approaches reduces time and financial expenses and increases the chances of positive results in anti-HIV R&D. To provide the scientific community with a tool that allows estimating of potential agents for treatment of HIV-infection and its comorbidities, we have created a freely-available web-resource for prediction of relevant biological activities based on the structural formulae of drug-like molecules.

resultsOver 50 000 experimental records for anti-retroviral agents from ChEMBL database were extracted for creating the training sets. After careful examination, about seven thousand molecules inhibiting five HIV-1 proteins were used to develop regression and classification models with the GUSAR software. The average values of R2 = 0.95 and Q2 = 0.72 in validation procedure demonstrated the reasonable accuracy and predictivity of the obtained (Q)SAR models. Prediction of 81 biological activities associated with the treatment of HIV-associated comorbidities with 92% mean accuracy was realized using the PASS program. AVAILABILITY AND IMPLEMENTATION: Freely available on the web at http://www.way2drug.com/hiv/. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

HIVHIV InfectionsPrednisoloneSoftwareViral ProteinsComputer SimulationProteinsStructure-Activity RelationshipPrednisoloneprednylideneProteinsViral Proteins

Identifiers

PMID31418763
PMCPMC7523681
OpenAlexW2969132997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.